AI-assisted, human-edited — this page is drafted with AI from public-source data, then reviewed before publication. How we use AI →
[Recalled] SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination — Product safety | Health Canada 2016-10-25
A safety authority has issued a recall or warning for this item. The confirmed facts from the source notice are laid out below.
Recall details
| Product | SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination |
|---|---|
| Category | Biologic or vaccine |
| Issuing authority | HC |
| Reference | 55712 |
| Country of notice | Canada |
| Hazard type | recall |
| Notice date | 25 October 2016 |
Why it was recalled
According to the HC notice, the identified hazard is: Product safety
This safety recall concerns Biologic or vaccine products distributed in Canada and was recorded by HC. Recalls in this category are published so that owners, retailers, and importers can identify affected units and act quickly.
What to do if you own this product
Review the official notice to confirm whether your unit is affected.
Read the full official notice →
This page indexes a public government recall notice for reference. We do not sell or verify this product; always confirm the current status on the authority's official site.
Shop Recalled SOLIRIS eculizumab Increased
As an Amazon Associate and eBay Partner, we may earn from qualifying purchases.
Explore by topic
Looking up a product? Use ProductGuru — free barcode & product database with 35M+ products. Search by EAN / UPC barcode.